84 related articles for article (PubMed ID: 19741712)
1. Valrubicin in a topical formulation treats psoriasis in a xenograft transplantation model.
Rosada C; Stenderup K; de Darkó E; Dagnaes-Hansen F; Kamp S; Dam TN
J Invest Dermatol; 2010 Feb; 130(2):455-63. PubMed ID: 19741712
[TBL] [Abstract][Full Text] [Related]
2. Topical application of valrubicin has a beneficial effect on developing skin tumors.
Andersen SM; Rosada C; Dagnaes-Hansen F; Laugesen IG; de Darkó E; Dam TN; Stenderup K
Carcinogenesis; 2010 Aug; 31(8):1483-90. PubMed ID: 20554745
[TBL] [Abstract][Full Text] [Related]
3. Valrubicin activates PKCa in keratinocytes: a conceivable mode of action in treating hyper-proliferative skin diseases.
Laugesen IG; Hauge E; Andersen SM; Stenderup K; de Darkó E; Dam TN; Rosada C
J Drugs Dermatol; 2013 Oct; 12(10):1156-62. PubMed ID: 24085052
[TBL] [Abstract][Full Text] [Related]
4. Topical valrubicin application reduces skin inflammation in murine models.
Hauge E; Christiansen H; Rosada C; de Darkó E; Dam TN; Stenderup K
Br J Dermatol; 2012 Aug; 167(2):288-95. PubMed ID: 22458650
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase 7A inhibitor ASB16165 impairs proliferation of keratinocytes in vitro and in vivo.
Goto M; Kadoshima-Yamaoka K; Murakawa M; Yoshioka R; Tanaka Y; Inoue H; Murafuji H; Kanki S; Hayashi Y; Nagahira K; Ogata A; Nakatsuka T; Fukuda Y
Eur J Pharmacol; 2010 May; 633(1-3):93-7. PubMed ID: 20132810
[TBL] [Abstract][Full Text] [Related]
6. Valrubicin.
Onrust SV; Lamb HM
Drugs Aging; 1999 Jul; 15(1):69-75; discussion 76. PubMed ID: 10459733
[TBL] [Abstract][Full Text] [Related]
7. 7-Chloro-5-(4-hydroxyphenyl)-1-methyl-3-(naphthalen-2-ylmethyl)-4,5-dihydro-1H-benzo[b][1,4]diazepin-2(3H)-one (Bz-423), a benzodiazepine, suppresses keratinocyte proliferation and has antipsoriatic activity in the human skin-severe, combined immunodeficient mouse transplant model.
Bhagavathula N; Nerusu KC; Hanosh A; Aslam MN; Sundberg TB; Opipari AW; Johnson K; Kang S; Glick GD; Varani J
J Pharmacol Exp Ther; 2008 Mar; 324(3):938-47. PubMed ID: 18055879
[TBL] [Abstract][Full Text] [Related]
8. Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin.
Dinney CP; Greenberg RE; Steinberg GD
Urol Oncol; 2013 Nov; 31(8):1635-42. PubMed ID: 22575238
[TBL] [Abstract][Full Text] [Related]
9. Factors affecting valrubicin response in patients with bacillus Calmette-Guérin-refractory bladder carcinoma in situ.
Steinberg GD; Smith ND; Ryder K; Strangman NM; Slater SJ
Postgrad Med; 2011 May; 123(3):28-34. PubMed ID: 21566413
[TBL] [Abstract][Full Text] [Related]
10. Rationale for intralesional valrubicin in chemoradiation of squamous cell carcinoma of the head and neck.
Wani MK; Koseki Y; Yarber RH; Sweatman TW; Ahmed A; Samant S; Hengesteg A; Israel M; Robbins KT
Laryngoscope; 2000 Dec; 110(12):2026-32. PubMed ID: 11129014
[TBL] [Abstract][Full Text] [Related]
11. BP-1107 [{2-[4-(2,4-dioxo-thiazolidin-5-ylmethyl)-phenoxy]-ethyl}-methyl-amide]: a novel synthetic thiazolidinedione that inhibits epidermal hyperplasia in psoriatic skin-severe-combined immunodeficient mouse transplants after topical application.
Bhagavathula N; Nerusu KC; Reddy M; Ellis CN; Chittiboyina A; Avery M; Pershadsingh HA; Kurtz TW; Varani J
J Pharmacol Exp Ther; 2005 Dec; 315(3):996-1004. PubMed ID: 16109743
[TBL] [Abstract][Full Text] [Related]
12. Stat3 as a therapeutic target for the treatment of psoriasis: a clinical feasibility study with STA-21, a Stat3 inhibitor.
Miyoshi K; Takaishi M; Nakajima K; Ikeda M; Kanda T; Tarutani M; Iiyama T; Asao N; DiGiovanni J; Sano S
J Invest Dermatol; 2011 Jan; 131(1):108-17. PubMed ID: 20811392
[TBL] [Abstract][Full Text] [Related]
13. Explorative immunohistochemical study to evaluate the addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis.
Bovenschen HJ; Gerritsen WJ; van Rens DW; Seyger MM; de Jong EM; van de Kerkhof PC
Arch Dermatol Res; 2007 Feb; 298(9):457-63. PubMed ID: 17136563
[TBL] [Abstract][Full Text] [Related]
14. Topical treatment with thiazolidinediones, activators of peroxisome proliferator-activated receptor-gamma, normalizes epidermal homeostasis in a murine hyperproliferative disease model.
Demerjian M; Man MQ; Choi EH; Brown BE; Crumrine D; Chang S; Mauro T; Elias PM; Feingold KR
Exp Dermatol; 2006 Mar; 15(3):154-60. PubMed ID: 16480422
[TBL] [Abstract][Full Text] [Related]
15. Topical application of a new monoclonal antibody against fibroblast growth factor 10 (FGF 10) mitigates propranolol-induced psoriasis-like lesions in guinea pigs.
Yao N; Xia JX; Liu XM; Wang N; Mmi XG; Wang YF; Guan LL; Yang J; Dong YY; Wang FW; Li HY; Li XK
Eur Rev Med Pharmacol Sci; 2014; 18(7):1085-91. PubMed ID: 24763891
[TBL] [Abstract][Full Text] [Related]
16. Topical treatment of mild to moderate plaque psoriasis with 0.3% tacrolimus gel and 0.5% tacrolimus cream: the effect on SUM score, epidermal proliferation, keratinization, T-cell subsets and HLA-DR expression.
Vissers WH; van Vlijmen I; van Erp PE; de Jong EM; van de Kerkhof PC
Br J Dermatol; 2008 Apr; 158(4):705-12. PubMed ID: 18284400
[TBL] [Abstract][Full Text] [Related]
17. Topical application of anti-angiogenic peptides based on pigment epithelium-derived factor can improve psoriasis.
Abe R; Yamagishi S; Fujita Y; Hoshina D; Sasaki M; Nakamura K; Matsui T; Shimizu T; Bucala R; Shimizu H
J Dermatol Sci; 2010 Mar; 57(3):183-91. PubMed ID: 20060688
[TBL] [Abstract][Full Text] [Related]
18. Ethyl acetate fraction of the root of Rubia cordifolia L. inhibits keratinocyte proliferation in vitro and promotes keratinocyte differentiation in vivo: potential application for psoriasis treatment.
Lin ZX; Jiao BW; Che CT; Zuo Z; Mok CF; Zhao M; Ho WK; Tse WP; Lam KY; Fan RQ; Yang ZJ; Cheng CH
Phytother Res; 2010 Jul; 24(7):1056-64. PubMed ID: 19960426
[TBL] [Abstract][Full Text] [Related]
19. Pulsed dye laser versus treatment with calcipotriol/betamethasone dipropionate for localized refractory plaque psoriasis: effects on T-cell infiltration, epidermal proliferation and keratinization.
Bovenschen HJ; Erceg A; Van Vlijmen-Willems I; Van De Kerkhof PC; Seyger MM
J Dermatolog Treat; 2007; 18(1):32-9. PubMed ID: 17365265
[TBL] [Abstract][Full Text] [Related]
20. Photophysical characterization of anticancer drug valrubicin in rHDL nanoparticles and its use as an imaging agent.
Shah S; Chib R; Raut S; Bermudez J; Sabnis N; Duggal D; Kimball JD; Lacko AG; Gryczynski Z; Gryczynski I
J Photochem Photobiol B; 2016 Feb; 155():60-5. PubMed ID: 26735001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
